- Home
- VYGR vs CHEC Comparison
VYGR vs CHEC Comparison
Compare VYGR & CHEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VYGR | CHEC |
|---|---|---|
| Founded | 2013 | 2024 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.3M | 175.5M |
| IPO Year | 2015 | 2025 |
Fundamental Metrics
Financial Performance| Metric | VYGR | CHEC |
|---|---|---|
| Price | $3.40 | $10.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 404.1K | 6.5K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,135,000.00 | N/A |
| Revenue This Year | $34.04 | N/A |
| Revenue Next Year | $7.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.94 | $9.91 |
| 52 Week High | $5.55 | $10.56 |
Technical Indicators
Market Signals| Indicator | VYGR | CHEC |
|---|---|---|
| Relative Strength Index (RSI) | 56.22 | 55.46 |
| Support Level | $3.33 | $10.15 |
| Resistance Level | $3.56 | $10.47 |
| Average True Range (ATR) | 0.16 | 0.01 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 74.03 | 12.50 |
Price Performance
Historical ComparisonAbout VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
About CHEC Chenghe Acquisition III Co. Class A Ordinary Share
Chenghe Acquisition III Co is blank check company.